Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03138980 · ClinicalTrials.gov registry record · NA

Mobile Self-Management of Irritable Bowel Syndrome for Adolescents

A NA study, sponsored by University of California, Los Angeles.

Completed
Registry status
NA
Development phase
26
Enrollment target

NCT03138980 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 26 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03138980, a NA study, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
NA
Development phase
26 participants
Enrollment target

Study Summary

The objective of the proposed research is to conduct user testing of a mobile-based self-management support intervention for adolescents and young adults with Irritable Bowel Syndrome (IBS), a chronic digestive condition. The application (app; BodiMojo Buddy) uses a virtual coach that can serve to increase patient engagement through interactive skill-building, self-care, and mindfulness-based cognitive behavioral activities. If the BodiMojo Buddy mobile app is successful, it will have a significant public health impact by providing a mobile resource to the 10-15% of the US population who suffer from IBS and potentially improving health outcomes and reducing significant costs to the US healthcare system. Study participation involves participants downloading and using the app for 30 days. During the 30 days, participants will interact with the app by inputting their current mood, receiving supportive feedback from the app, reading messages, and doing brief activities (such as relaxation activities, etc.). Before and after the 30 days of user testing, participants will complete a few brief questionnaires about their behavior, how their symptoms affect their life, and how they receive support from others. These questions will take around 20 minutes to complete at each administration.

Interventions

  • BEHAVIORAL BodiMojo Buddy for IBS

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2016-01-30
Est. Completion 2016-09-22
Phase NA

What the Registry Record Tells You About NCT03138980

The ClinicalTrials.gov registry entry for NCT03138980 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which BodiMojo Buddy for IBS is the first listed.

NCT03138980 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03138980 about?

NCT03138980 is a clinical study titled "Mobile Self-Management of Irritable Bowel Syndrome for Adolescents". The objective of the proposed research is to conduct user testing of a mobile-based self-management support intervention for adolescents and young adults with Irritable Bowel Syndrome (IBS), a chronic digestive condition. The application (app; BodiMojo Buddy) uses a virtual coach that can serve to i...

What is the current status of trial NCT03138980?

This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2016-01-30. Estimated completion is 2016-09-22.

What interventions are being tested in trial NCT03138980?

The interventions under investigation include: BodiMojo Buddy for IBS (BEHAVIORAL).

Who is sponsoring clinical trial NCT03138980?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.